CClinicalTrials.gg
CompletedNCT03418259Updated Dec 13, 2022

Intra-Nasal Mechanical Stimulation (INMEST) as a Treatment of Keratoconjunctivitis Sicca (Dry Eye Syndrome)

An interventional study of KCS Medical Device and KCS Medical Device in Keratoconjunctivitis Sicca (KCS), sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-13.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate how treatment with Intra-Nasal Mechanical Stimulation (INMEST) in the nasal cavity in patients with Keratoconjunctivitis sicca can relieve these symtoms.

02

Conditions studied

03

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Ocular surface disease index, OSDI > 12 points.
  • Non-invasive breakup time, NIBUT \< 11 seconds.

Exclusion criteria

Exclusion Criteria:

  • Ocular surface disease index, OSDI \< 12 points.
  • Non-invasive breakup time, NIBUT > 11 seconds.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Active KCS Medical Device

    Device: KCS Medical Device

  • Placebo comparator
    Inactive KCS Medical Device

    Device: KCS Medical Device

Interventions

  • DeviceKCS Medical Device

    Patient treated 6 times with the Active KCS Medical Device during 2 weeks.

  • DeviceKCS Medical Device

    Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.

05

What researchers measure

Primary outcomes

  1. Ocular surface disease index, OSDI

    12-item scale for the assessment of symptoms related to dry eye disease and their effect on vision. Scale 0-100, normal value range 0-12.

    Time frame: Change from Baseline Ocular surface disease index at two weeks.

Secondary outcomes

  1. Noninvasive breakup time, NIBUT

    Assessment of tear film stability. Normal value at least 11 seconds.

    Time frame: Change from Baseline Noninvasive breakup time at two weeks.

  2. Meibography

    Imaging study method for directly visualizing the morphology of Meibomian glands in vivo. Fat amount in the Meibomian glands is quantified and stated in percent. A Meibo scale value over 25 % is considered abnormal.

    Time frame: Change from Baseline Meibo scale value at two weeks.

  3. Phenol Red Thread Test, PRT

    Measurement of lacrimation, stated in millimetres. Normal value is 12-20 millimetres.

    Time frame: Change from Baseline lacrimation assessed with Phenol Red Thread Test value at two weeks.

  4. Tear (lacrimal) meniscus height

    Tear meniscus height measured medially on the lower eyelid. Stated in millimetres. Normal value is over 0,2 mm.

    Time frame: Change from Baseline Tear (lacrimal) meniscus height at two weeks.

  5. Lissamin green test

    A strip of paper containing lissamine green is diluted with saline, and then dropped into the eye. The colour of the paper will disclose any dry cell patches in the eye.

    Time frame: Change from Baseline spread of dry cell patches quantified with Lissamin green test at two weeks.

  6. Corneal staining with fluorescein

    Fluorescein is used to describe the severity of damaged epithelial cells on cornea. Efron Grading Scale, 1-5. 0 is normal value.

    Time frame: Change from Baseline Efron Grading Scale value at two weeks.

06

Study locations

1 site
  • Källmarkskliniken
    Stockholm, Sweden
07

Registry details

Key details

Study ID
NCT03418259
Lead sponsor
Karolinska Institutet
Collaborators
Källmark Clinic
Responsible party
Jan-Erik Juto (Principal Investigator, M.D., Ph.D., Karolinska Institutet) — Principal investigator
First posted
Feb 1, 2018
Start date
Feb 12, 2018
Primary completion
Jul 1, 2022
Completion
Jul 1, 2022
Last update
Dec 13, 2022

Study contacts

Jan-Erik Juto, M.D., Ph.D.
principal investigator · Department of Clinical Science, Intervention and Technology (CLINTEC), H9, Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion